Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
Obesity is a growing epidemic, and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs that aim to cause effective weight loss with minimal side effects. Both glucagon and GLP-1 reduce appetite and cause weight loss. Additionally, glucagon increases energy expenditure. We hypothesized that the combination of both peptides, administered at doses that are individually subanorectic, would reduce appetite, while GLP-1 would protect against the hyperglycemic effect of glucagon. In this double-blind crossover study, subanorectic doses of each peptide alone, both peptides in combination, or placebo was infused into 13 human volunteers for 120 min. An ad libitum meal was provided after 90 min, and calorie intake determined. Resting energy expenditure was measured by indirect calorimetry at baseline and during infusion. Glucagon or GLP-1, given individually at subanorectic doses, did not significantly reduce food intake. Coinfusion at the same doses led to a significant reduction in food intake of 13%. Furthermore, the addition of GLP-1 protected against glucagon-induced hyperglycemia, and an increase in energy expenditure of 53 kcal/day was seen on coinfusion. These observations support the concept of GLP-1 and glucagon dual agonism as a possible treatment for obesity and diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
New methods for calculating metabolic rate with special reference to protein metabolism
Weir, J. B. D. V. (1949) · The Journal of Physiology · doi:10.1113/jphysiol.1949.sp004363 · Cited by 5,603 · cited 1×
“Resting energy expenditure (REE), respiratory quotient (RQ), and carbohydrate and fat oxidation rates were calculated from the VO2 and VCO2 measured at 1-min intervals, and adjusted for urinary nitrogen excretion (27,28).”
MethodThe thrifty phenotype hypothesis
Hales, C. N., & Barker, D. J. P. (2001) · British Medical Bulletin · doi:10.1093/bmb/60.1.5 · Cited by 2,738 · cited 1×
“The current study was therefore designed to demonstrate the acute effects of intravenous infusion of GLP-1 and glucagon when given at low doses, both alone and in combination, on food intake (22), glucose homeostasis, and energy expenditure in humans.”
BackgroundCalculation of substrate oxidation rates in vivo from gaseous exchange.
Frayn, K. N. (1983) · Journal of Applied Physiology · doi:10.1152/jappl.1983.55.2.628 · Cited by 2,365 · cited 1×
“Resting energy expenditure (REE), respiratory quotient (RQ), and carbohydrate and fat oxidation rates were calculated from the VO2 and VCO2 measured at 1-min intervals, and adjusted for urinary nitrogen excretion (27,28).”
MethodChanges in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“Appetite inhibition classically results in defense of body weight by a reduction of energy expenditure (7,8).”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 3×
“GLP-1’s insulinotropic effects are dependent on the prevailing glucose level (10), which accounts for the relatively small insulinotropic response observed during GLP-1 infusion alone, as glucose levels tend to decline after the start of the infusion (Fig.”
BackgroundMethodSelf-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416 · cited 1×
“Any abnormal eating behavior was assessed using the Dutch Eating Behavior Questionnaire (23) and the SCOFF questionnaire (24).”
MethodGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“The postprandial nausea seen in this study may instead be accounted for by a delay in gastric emptying triggered by glucagon and GLP-1 (31,32).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“As a result, GLP-1 is capable of achieving a modest reduction in body weight (12).”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Co-infusion of GLP-1 and glucagon to human subjects resulted in decreased food intake, likely secondary to GLP-1 action, and increased energy expenditure, suggested to be driven by glucagon action [783,785].”
BackgroundSelf-citationA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 494
“Nevertheless, several studies [50] also verified that acute co-infusion of low doses of GLP-1 and glucagon significantly reduced food intake and increased energy expenditure and this effect was achieved with peptide infused alone as well.”
BackgroundThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The preclinical results are beginning to be corroborated by observations in non-human primates (274, 588) and clinical studies, which show that co-infusion of GLP-1 and glucagon decreases food intake (96) while increasing energy expenditure (575).”
ResultSignaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
“In humans, coadministration of GLP-1 and glucagon results in a superior reduction in food intake than either GLP-1 or glucagon alone.(557) Besides, GLP-1 can neutralize hyperglycemia caused by glucagon,(558) and polypharmacy can achieve the same reduction in food intake or increase in energy expenditure at fewer doses.”
Background
Metadata
- Authors
- Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., Minnion, J., Cuenco, J., Ghatei, M. A., Meeran, K., Tan, T. M., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Bloom, Stephen R.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-10-13
- Volume
- 63
- Issue
- 11
- Pages
- 3711-3720
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2115939390
- Cited by
- 159
- References
- 49
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 19 · 2023: 14 · 2022: 10 · 2021: 15 · 2020: 13 · 2019: 12 · 2018: 16 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 1
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (ACF-2007-21-023, ACF-2010-21-012, ACF-2010-21-017)
- Imperial College Healthcare NHS Trust
- National Institutes of Health
- Medical Research Council (MR/J010936/1, MR/K02115X/1, MR/K023667/1, MR/J010731/1)
- Biotechnology and Biological Sciences Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- glucagon-like peptide-1, glucagon, dietary intake, appetite, obesity, weight loss, satiety hormones, energy expenditure, hyperglycemia, diabetes treatment
- MeSH terms
- Adult, Eating, Glucagon, Humans, Hyperglycemia, Male, Cross-Over Studies, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.